Series A · Biotech · Zurich, Switzerland · Founded 2014 · 20–25 employees
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing novel human immunomodulatory proteins targeting innate and adaptive immunity for cancer and inflammatory diseases. Founded in 2014 as a spin-off from University of Zurich and Basel, it has a differentiated HLA-based pipeline including lead IOS-1002 in Phase 1a/b trials. The company raised CHF 15M Series A in 2019 co-led by Pfizer Ventures and BioMedPartners, and most recently USD 11M on September 18, 2024, bringing total funding to $99.2M.
No open roles listed right now.